Long-term efficacy of dupilumab in patients with moderate-to-severe type 2 inflammation by age of asthma onset: LIBERTY ASTHMA TRAVERSE study

被引：0
|
作者：
Busse, William W. [1 ]
Kraft, Monica [2 ]
Domingo, Christian [3 ]
de Mir, Ines [4 ]
Maselli, Diego [5 ]
Xia, Changming [6 ]
Pandit-Abid, Nami [7 ]
Soler, Xavier [8 ]
Jacob-Nara, Juby A. [9 ]
Sacks, Harry [10 ]
Rowe, Paul J. [11 ]
Deniz, Yamo [12 ]
机构：
[1] Univ Wisconsin, Sch Med & Publ Hlth, UW Allergy Pulm & Crit Care Med, Madison, WI 53706 USA
[2] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[3] Univ Autonoma Barcelona, Pulm Serv, Barcelona, Spain
[4] Hosp Valle De Hebron, Pulm Funct Lab, Barcelona, Spain
[5] UT Hlth, San Antonio, TX USA
[6] Regeneron Pharmaceut Inc, Stat, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[7] Sanofi, Global Med Affairs, Bridgewater, MA USA
[8] Regeneron Pharmaceut Inc, Dept Med, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[9] Sanofi, Global Med Affairs Resp Allergy & Gastroenterol, Bridgewater, MA USA
[10] Regeneron Pharmaceut Inc, Immunol & Inflammat, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[11] Sanofi, Global Med, Immunol, Bridgewater, MA USA
[12] Regeneron Pharmaceut Inc, Global Clin Dev, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AO01-1
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Impact of age of asthma onset on the long-term efficacy of Dupilumab in patients with type 2 inflammation: Liberty asthma traverse study
    Busse, W. W.
    Kraft, M.
    Domingo, C.
    De Mir, I.
    Maselli, D.
    Soler, X.
    Xia, C.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Deniz, Y.
    ALLERGY, 2023, 78 : 54 - 55
  • [2] Long-term efficacy of dupilumab in patients with type 2 asthma by age at onset: LIBERTY ASTHMA TRAVERSE
    Busse, W. W.
    Kraft, M.
    Domingo, C.
    De Mir, I.
    Maselli, D. J.
    Soler, X.
    Xia, C.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H.
    Rowe, P. J.
    Deniz, Y.
    ALLERGOLOGIE, 2023, 46 (08) : 543 - 544
  • [3] Long-Term Dupilumab Efficacy in Patients with Type 2 Asthma by Age of Onset: Liberty asthma traverse
    Busse, William
    Kraft, Monica
    Domingo, Christian
    De Mir, Ines
    Maselli, Diego J.
    Soler, Xavier
    Xia, Changming
    Pandit-Abid, Nami
    Jacob-Nara, Juby A.
    Sacks, Harry
    Rowe, Paul J.
    Deniz, Yamo
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [4] Long-Term Dupilumab Treatment in Moderate-to-Severe Asthma with Type 2 Inflammation: Open Label LIBERTY ASTHMA TRAVERSE Study
    Wechsler, M.
    Pavord, I. D.
    Papi, A.
    Chapman, K. R.
    Mao, X.
    Ortiz, B.
    Djandji, M.
    Ruddy, M. K.
    Laws, E.
    Amin, N.
    Lederer, D. J.
    Hardin, M. E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [5] Long-term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: The Liberty Asthma Traverse Continuation Study
    Maspero, J. F.
    Peters, A.
    Chapman, K. R.
    Domingo, C.
    Stewart, J.
    Hardin, M.
    Maroni, J.
    Tawo, K.
    Khokhar, F. A.
    Mortensen, E.
    Laws, E.
    Radwan, A.
    Jacob-Nara, J. A.
    Deniz, Y.
    Rowe, P. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [6] Long-term safety of dupilumab in patients with moderate-to-severe asthma who completed the liberty asthma traverse continuation study
    Maspero, J.
    Peters, A.
    Chapman, K.
    Domingo, C.
    Stewart, J.
    Hardin, M.
    Maroni, J.
    Tawo, K.
    Khokhar, F. A.
    Mortenson, E.
    Laws, E.
    Amr, R.
    Jacob-Nara, J. A.
    Deniz, Y.
    Rowe, P. J.
    ALLERGY, 2023, 78 : 188 - 189
  • [7] Impact of Early Transient Increase in Eosinophil Count on the Long-term Efficacy of Dupilumab in Patients With Moderate-to-Severe Asthma: Liberty Asthma Traverse
    Lugogo, N. L.
    Pavord, I. D.
    Castro, M.
    Papi, A.
    Bourdin, A.
    Wechsler, M. E.
    Cote, A.
    Xia, C.
    Soliman, M.
    Pandit-Abid, N.
    Jacob-Nara, J. A.
    Sacks, H. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [8] LONG-TERM EFFICACY OF DUPILUMAB: 3-YEAR DATA OF QUEST PATIENTS WITH MODERATE-TO-SEVERE ASTHMA ENROLLED IN LIBERTY ASTHMA TRAVERSE
    Pavord, I. D.
    Papi, A.
    Bourdin, A.
    Watz, H.
    Domingo, C.
    Wechsler, M. E.
    Mao, X.
    Ortiz, B.
    Djandji, M.
    Mannent, L.
    Laws, E.
    Amin, N.
    Lederer, D. J.
    Hardin, M.
    THORAX, 2021, 76 : A53 - A54
  • [9] Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study
    Maspero, Jorge F.
    Peters, Anju T.
    Chapman, Kenneth R.
    Domingo, Christian
    Stewart, John
    Hardin, Megan
    Maroni, Jaman
    Tawo, Kelsey
    Khokhar, Faisal A.
    Mortensen, Eric
    Laws, Elizabeth
    Radwan, Amr
    Jacob-Nara, Juby A.
    Deniz, Yamo
    Rowe, Paul J.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (04): : 991 - 997.e6
  • [10] Long-Term Efficacy of Dupilumab in Quadrants of Elevated- vs Low- Type 2 Biomarker Patients With Uncontrolled, Moderate-to-Severe Asthma: LIBERTY ASTHMA TRAVERSE
    Wechsler, Michael
    Pavord, Ian
    Papi, Alberto
    Chapman, Kenneth
    Mao, Xuezhou
    Ortiz, Benjamin
    Djandji, Michel
    Jacob-Nara, Juby
    Rowe, Paul
    Deniz, Yamo
    Laws, Elizabeth
    Akinlade, Bolanle
    Amin, Nikhil
    Lederer, David
    Hardin, Megan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB190 - AB190
12345